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Abstract
Background Regular outpatient follow-up programmes are
usually offered to patients following treatment for gynae-
cological and other cancers. Despite the substantial
resources involved in providing these programmes, there is
evidence that routine follow-up programmes do not affect
survival or the likelihood of detecting recurrence and may
not meet patient needs. Alternative follow-up modalities
may offer the same outcomes at lower cost. We examined
the costs of using telephone-based routine follow-up of
women treated for endometrial cancer undertaken by spe-
cialist gynaecology oncology nurses in comparison to
routine hospital-based follow-up.
Methods The ENDCAT trial randomised 259 women at
five centres in the north west of England with a known
diagnosis of Stage I endometrial cancer who had completed
primary treatment on a 1:1 basis to receive either standard
hospital outpatient follow-up or a telephone follow-up
intervention administered by specialist nurses. A cost-
consequence analysis was undertaken in which we com-
pared costs to the health system and to individuals with the
trial’s co-primary outcomes of psychological morbidity
and participant satisfaction with information received.
Results Psychological morbidity, psychosocial needs,
patient satisfaction and quality of life did not differ
between arms. Patients randomised to telephone follow-up
underwent more and longer consultations. There was no
difference in total health service mean per patient costs at
6 months (mean difference £8, 95% percentile confidence
interval: - £147 to £141) or 12 months (mean difference:
- £77, 95% percentile confidence interval: - £334 to
£154). Estimated return journey costs per patient for hos-
pital consultations were £11.47. Productivity costs were
approximately twice as high under hospital follow-up.
Conclusion Telephone follow-up was estimated to be cost-
neutral for the NHS and may free up clinic time for other
patients. There was some evidence that telephone follow-
up may be more efficient for patients and wider society,
and is not associated with additional psychological mor-
bidity, lower patient satisfaction or reduced quality of life.
Trial Registration ISRCTN: 75220876, prospectively
registered 28 October 2011.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40258-018-0378-6) contains supple-
mentary material, which is available to authorized users.
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Key Points for Decision Makers
Telephone-based follow-up patients following
treatment for gynaecological and other cancers is an
acceptable alternative to regular hospital-based
outpatient follow-up programmes.
The ENDCAT trial compared NHS and personal
costs in up to 259 patients randomised to receive
either hospital or telephone-based follow-up after
treatment for Stage I endometrial cancer.
Telephone-based follow-up was no worse for
psychological morbidity than hospital-based follow-
up, was not more expensive to the health system than
hospital-based follow-up and may be associated with
lower personal costs.
1 Background
Over two million people are currently living with and
beyond cancer in the United Kingdom (UK), a figure es-
timated to rise to four million by 2030 [1]. Cancer-care
pathways indicate that the highest numbers of patients are
in the post-treatment rehabilitation and monitoring phases
[2]. This follow-up stage usually involves hospital outpa-
tient appointments on a regular basis for a number of years.
The purpose of follow-up is to detect recurrence of cancer
at an early stage with the aim of extending survival and/or
improving quality of life [3]. Providing follow-up care
post-treatment is likely to be extremely challenging, given
the increasing numbers combined with finite healthcare
resources. In addition, there is little evidence to support a
survival advantage from hospital-based follow-up for dif-
ferent types of cancer [3–5]. A recent Cancer Taskforce
report emphasised the need for efficiency savings and the
evaluation of alternative approaches to hospital-based fol-
low-up after treatment for cancer [6].
Alternative modalities of follow-up may offer a means
of achieving better outcomes at lower cost [7]. This study
describes an investigation of the costs and impact on psy-
chological morbidity, patient satisfaction and quality of life
of nurse-led, telephone-based follow-up in comparison to
routine, doctor- or nurse-led, hospital-based outpatient
appointments following treatment for Stage I endometrial
cancer. Globally, there were estimated to be 320,000
incident cases of endometrial cancer in 2012, associated
with 76,000 deaths [8]. Stage I endometrial cancer, which
is confined to the uterus, accounts for 75% of all diagnoses
of the disease [9], and is associated with mean 5-year
survival of greater than 70% [10, 11]. Early-stage
endometrial cancer has a low risk of recurrence and the
majority of recurrences are symptomatic [12]. Hence, less
clinically intensive follow-up approaches may be justified
for this patient group.
The aim of the analysis was to estimate the costs and
consequences of using telephone-based routine follow-up
of women treated for endometrial cancer undertaken by
specialist gynaecology oncology nurses in comparison to
routine management using doctor-led hospital-based fol-
low-up.
2 Methods
The ENDCAT trial randomised 259 women on a 1:1 basis
between January 2012 and January 2014 at five centres in
the north-west of England (Fig. 1). Details of trial methods
were published in the study protocol [13] and in the paper
describing the results of the trial [14]. In brief, women with
a known diagnosis of Stage I endometrial cancer who had
completed primary treatment and were attending outpatient
clinics for the purposes of routine monitoring and
surveillance were eligible for inclusion. No restrictions on
age were imposed. Trial participants received either stan-
dard hospital outpatient follow-up led by either doctors or
nurse specialists (in the control arm) or a telephone follow-
up intervention administered by specialist gynaecology
oncology nurses.
The trial was designed to assess non-inferiority in the
co-primary outcome of psychological morbidity using the
state anxiety scale of the State Trait Anxiety Inventory
(STAI) [15]. STAI measures an individual’s tendency to
anxiety as a stable trait as well as a transitory state. The
measure consists of 20 items related to state anxiety (e.g. I
am tense) and 20 related to trait (e.g. I feel inadequate).
Each item is measured on a 4-point scale ranging from ‘not
at all’ to ‘very much so’ for state and ‘almost never’ to
‘almost always’ for trait.
In addition, the ENDCAT trial assessed superiority in
terms of the co-primary outcome of patient satisfaction
with information received patient satisfaction (measured
using questionnaires [14]), and superiority in the secondary
outcome of efficiency as measured by cost differences
between arms. Patient satisfaction with information was
measured by asking participants the following question—
‘Did you get all the information you needed at your hos-
pital or telephone appointment?’. Participants were asked
to indicate one of five possible responses: ‘I got all/-
most/some/none of the information I needed’ or ‘I did not
need any information’.
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The sample size for the randomised controlled trial
(RCT) was based on a pre-specified noninferiority margin
for the effect of the intervention on the STAI scale. Quality
of life was measured using the European Organization for
Research and Treatment (EORTC) QLQ-C30 (version 3)
instrument [16] and an endometrial cancer-specific module
(QLQ-EN24) [17]. Outcomes were measured at baseline
and the first post-baseline appointment (which could be
between 3 and 12 months after baseline depending on
follow-up schedule).
The EORTC QLQ-C30 is a 30-item measure that
includes five functional scales (physical, role, cognitive,
emotional, social), three symptom scales (fatigue, nausea
and vomiting, pain) and six single items; four-point scales
range from ‘not at all’ to ‘very much’. An overall general
health scale and an overall quality-of-life scale are also
included; seven-point scales ranging from ‘very poor’ to
‘excellent’. The EN24 is designed to be used in conjunc-
tion with the EORTC QLQ-C30 and consists of 24 items
with three functional scales (sexual interest, function and
activity) and 10 symptom scales (e.g. hair loss, urological
symptoms). Items are rated on a four-point scale ranging
from ‘not at all’ to ‘very much’.
More detailed analyses of the ENDCAT trial’s outcomes
been reported previously [14]. To undertake a cost-conse-
quence analysis, we compared costs for up to 12 months’
post-randomisation that were associated with each follow-
up strategy in the context of the co-primary outcomes of
the trial. The costs included those associated with health
system resource use, such as nurse and doctor time, and
diagnostic tests. This form of analysis, known as cost-
consequence analysis, allows decision makers to compare
explicitly the costs associated with hospital and telephone
follow-up with the outcomes studied in the trial [18].
Healthcare use was assessed using information from a
patient-completed resource use questionnaire (RUQ), from
case report forms (CRFs), and from reviews of medical
notes. A specimen example of the RUQ is included in
supplementary material. All RUQs dispatched within ±
14 days of the 6- and 12-month post-randomisation dates
were considered valid for analysis. A small number of
patients recruited during the final 6 months of the
Fig. 1 Randomised patients analysed by arm
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recruitment period were asked to provide only 6 months of
follow-up information.
The RUQ (6 and 12 months) consisted of 11 questions
related to healthcare use in both primary care [general
practitioner (GP) and community nursing services] and
secondary care as well as one open question providing an
opportunity for comments. Participants were asked to
indicate how many times they had contacted a specific
healthcare service in the last 6 months; seven options were
available ranging from ‘more than once a week’ to ‘never’.
For all participants who attended hospital outpatient
appointments a Record of Visit form (CRF) was completed
at each attendance and the following information was
recorded (if applicable): type of visit (e.g. scheduled,
interval), who conducted the consultation, tests and
investigations ordered, referrals to other services, indica-
tions of recurrent disease, and duration of appointment. For
all participants who received telephone consultations, the
same information was recorded on a Record of Telephone
Consultation form. The Medical Notes Review form
enabled a final cross-checking of data on number of
appointments (both hospital and telephone), diagnosis of
recurrent disease, hospital admissions (related and unre-
lated to cancer diagnosis) and current status (e.g. continu-
ing on follow-up, discharged, died).
2.1 Training of Nurses for Telephone Follow-Up
Nurses were trained to provide routine telephone follow-
up. This training took place in NHS hospital facilities and
used no specialised services or capital equipment. The
training programme included initial training sessions and a
feedback session. The training involved discussions on the
rationale for telephone follow-up, skills required to deliver
the intervention over the telephone, and a detailed explo-
ration of how to respond to patient information needs.
NHS nurses are remunerated according to ‘bands’ of
pay, with higher bands indicating greater seniority and
higher pay. Five Band 7 nurses received 6 hours of training
from one senior academic nurse (equivalent to Band 8a),
and one hour of feedback from two senior academic nurses.
Staff attrition and the addition of a new study site required
two more nurses (1 Band 8 and 1 Band 6) to receive two
hours of training each without a formal feedback session. It
was assumed that, in practice, the training would typically
be led by a senior nurse (either Band 7 or Band 8a), and we
assumed that this nurse would be a Band 8a nurse for the
purposes of costing the intervention.
It is possible that nurse training is needed only once to
deliver telephone follow-up, and therefore the costs of this
training should be amortised over the working lives of
nurses receiving the training. The base-case analysis
includes training cost over the (relatively short) period of
the trial follow-up, while sensitivity analysis excludes
training costs from the between-arm cost comparison.
2.2 Sources of Information on Participant
Characteristics, Healthcare and Other Costs
Baseline information on age, marital status, employment,
education, and occupational grouping was collected using
questionnaires. Travel time, mode of transport and
patient/companion time off from work for the hospital
follow-up appointment were collected from questionnaires
completed by patients at the first post-randomisation
appointment, and responses were taken to be representative
of the patient and family burden for all subsequent
appointments. We assumed that employment status did not
change during follow-up and that those in employment
worked eight hours per day (four hours per day for those
working part-time).
Telephone appointments were routinely audio recorded,
which allowed for consultation duration to be recorded.
The durations of hospital appointments were timed or
estimated. Research nurses completed CRFs for clinic
visits and telephone consultations during, or shortly after,
the consultation. CRFs recorded the duration of the
appointment, grade of clinician/band of nurse, referrals,
tests or investigations ordered, whether the patients were
accompanied on hospital visits, and any signs of
recurrence.
Medical notes reviews provided information on cancer-
related admissions, recurrence and metastases, date of
death and whether death was related to endometrial can-
cer—these were an alternative source of information on
follow-up appointments. Data on other resource use—such
as GP visits – were collected from the RUQs sent to
patients at 6 and 12 months’ post-randomisation.
2.3 Unit Cost of Resource Items
Unit cost data (Table 1) were drawn primarily from two
national sources: the unit costs of health and social care
[19] and NHS Reference Costs [20]. The cost of a nurse or
doctor contact hour included salary (excluding overtime
and shift payments), on-costs (e.g. national insurance
contributions), qualifications, the ratio of patient contact to
non-contact time, and overheads.
We collected unit cost data from 2012/13 as this was
approximately the mid-point of trial recruitment. Unit costs
from this period therefore reflect the structure of relative
costs prevailing within the NHS at the time of the trial. We
inflated unit costs from the time of the trial using the most
recent (2016/17) UK GDP deflator [21] (an established
measure of general inflation) so that costs are expressed in
pounds sterling at 2016/17 prices. Other details on the
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Table 1 Unit cost data
Resource Unit cost in
2012/13
prices (£)
Unit cost in
2016/17
prices (£)a
Data source for
unit cost
valuation
Data source for duration of consultation
used in cost calculations
Nurse training for telephone consultation
Nurse training, including feedback sessions 2958.95 3143.00 UCHSCd 2013
Consultations
Telephone consultations
Band 7 nurse, per patient-related hour 70.02 74.38 UCHSC 2013 Data collected in trial
Band 8a nurse, per patient-related hour 78.49 83.37 UCHSC 2013 Data collected in trial
Cost of landline phone call per minute 0.09 0.10 BTb Data collected in trial
Hospital consultations
Consultant doctor, per patient-related hour 246.31 261.63 UCHSC 2013 Data collected in trial
Registrar doctor, per patient-related hour 106.07 112.67 UCHSC 2013 Data collected in trial
F2/FI: Average of Foundation year 2 and year 1,
per patient-related hour
65.86 69.96 UCHSC 2013 Data collected in trial
Nurse specialist, per patient-related hour 103.85 110.31 UCHSC 2013 Data collected in trial
Private car rates per mile 0.45 0.48 HMRCb
Hospital parking per consultation 2.07 2.20 Hospital data
Median 4-h wage of patient 46.48 49.37 Annual Survey of
Hours and
Earnings [34]
Hospital transport services 13.58 14.42 Liu et al. [35]
Tests (HRG code)c
Computerised tomography (RA08A-RA14Z) 106.38 113.00 Reference Costs
2012/13c
Ultrasonography (RA23Z-RA24Z) 51.88 55.11 Reference Costs
2012/13
Diagnostic hysteroscopy with biopsy (MA32Z) 846.25 898.89 Reference Costs
2012/13
Mid-stream urine sample (DAPS04) 1.25 1.33 Reference Costs
2012/13
Blood tests (DAPS03) 1.94 2.06 Reference Costs
2012/13
Wound swab/bile culture test/histology/high
vaginal swab (DAPS02)
38.74 41.15 Reference Costs
2012/13
Referrals (HRG code)
Community-based physiotherapist per-patient
related hour
75.11 79.78 UCHSC 2013 Based on 30-min consultation, UCHSC
2010e
Complementary therapies, not otherwise
specified—costed as non-admitted, non-
consultant attendance (WF01A-WF02D)
62.93 66.84 Reference Costs
2012/13
GP consultation at practice 45.00 47.80 UCHSC 2013 Based on 11.7-min consultation,
UCHSC 2013
Hospital-based physiotherapist per patient-
related hour
79.87 84.84 UCHSC 2013 Based on 23.3-min consultation,
UCHSC 2010
Multi-disciplinary teams (CMDT_SpG) 112.49 119.49 Reference Costs
2012/13
Psychologist/counsellor per patient-related hour 131.40 139.57 UCHSC 2013 Based on assumed duration of 60 min
Radiologist per patient-related hour 36.72 39.00 UCHSC 2013 Based on 20-min consultation, UCHSC
2010
Urodynamics (LB42A) 396.69 421.37 Reference Costs
2012/13
Costs of Hospital Versus Telephone Follow-Up after Endometrial Cancer
construction of unit costs are provided in online supple-
mentary material.
2.4 Perspective
The primary economic analysis took a health system (i.e.
NHS) perspective for costs and focussed on routine mon-
itoring and surveillance costs. The perspective of an eco-
nomic evaluation establishes which costs should be
measured, how these costs should be valued, and how they
should be related to the consequences of interest. A health-
system perspective is most relevant to those involved in
funding and commissioning health services.
The time horizon for the economic analysis was up to
12 months. Costs were not discounted. We excluded costs
known to be incurred post-recurrence, or collected from
RUQs returned post-recurrence, on the grounds that time
until recurrence detection is not causally related to the
mode of routine follow-up [22, 23]. In secondary analysis
we examined healthcare costs associated with recurrence
and estimated personal (e.g. travel) and productivity (i.e.
time off work) costs.
2.5 Analysis Sample
Three women (2 telephone arm, 1 hospital arm) withdrew
from the trial at their own request and provided no
Table 1 continued
Resource Unit cost in
2012/13
prices (£)
Unit cost in
2016/17
prices (£)a
Data source for
unit cost
valuation
Data source for duration of consultation
used in cost calculations
Other healthcare used during follow-up
Community-based occupational therapy per
patient-related hour
75.13 79.80 UCHSC 2013 Based on 40-min consultation, UCHSC
2010
District nurse per patient-related hour 69.97 74.32 UCHSC 2013 Based on 20-min consultation, UCHSC
2010
GP home visit 114.00 121.09 UCHSC 2013 Based on 23.4-min consultation,
UCHSC 2013
GP phone consultation 27.00 28.68 UCHSC 2013 Based on 7.1-min consultation,
UCHSC 2013
Hospital genetics (WF01A-WF01D) 193.74 205.79 Reference Costs
2012/13
Hospital incontinence clinic 139.23 147.89 UCHSC 2013 Based on assumed duration of 60 min,
costed as the time of one specialist
hospital-based nurse
Hospital occupational therapy per patient-related
hour
79.84 84.81 UCHSC 2013 Based on 30-min consultation, UCHSC
2010
Hospital pain team (AB03Z-AB06Z) 175.91 186.85 Reference Costs
2012/13
Hospital secretary/receptionist per contracted
hour
33.67 35.76 UCHSC 2013 Based on assumed duration of 15 min
Mental health services 136.00 144.46 UCHSC 2013
Other community specialist nurse per patient-
related hour
62.85 66.76 UCHSC 2013 Based on assumed duration of 15 min
Practice nurse per patient-related hour 51.49 54.69 UCHSC 2013 Based on 15.5-min consultation,
UCHSC 2010
Walk-in centre 41.96 44.57 UCHSC 2011
a2016/17 prices based on UK GDP deflator at market prices
bBT: BT Group plc, the major telephone landline provider in the UK. HMRC: Her Majesty’s Revenue and Customs
cIf sufficient detail was not available from medical notes, the averages of ‘Currency Code’ costs from NHS Reference Costs were calculated by
weighting the total number of finished consultant episodes across all service descriptions
dUCHSC 2013 refers to [19]. UCHSC 2011 refers to [36]. UCHSC 2010 refers to [37]
eWhen UCHSC was used as the source of data for the duration of a typical appointment, the most recently available data were used where
possible
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resource-use follow-up data. Two women (1 in each arm)
died from causes unrelated to endometrial cancer before
they received any follow-up or provided resource-use data.
These five patients were excluded from all economic
analyses. We analysed the remaining patients in the groups
to which they were randomised.
Analysis was conducted on available cases. Patients
were eligible for inclusion in the six-month analysis if they
had returned the 6-month RUQ and had undergone at least
one follow-up consultation. Patients were eligible for
inclusion in the 12-month analysis if they underwent at
least one follow-up consultation and returned both 6- and
12-month RUQs (Fig. 1).
2.6 Missing Data
Missing data were infrequent (Fig. 1), and logistic regres-
sion analysis confirmed that ‘‘missingness’’ was not asso-
ciated with allocation at 6 or 12 months. Missing responses
to specific resource-use questions on otherwise complete
RUQs were taken as null responses, i.e. a response that the
resource in question had not been used.
2.7 Subgroup Analysis
The pre-specified subgroups were aligned to the subgroup
variables used in the ENDCAT clinical effectiveness
analysis [14]: routine follow-up interval at recruitment
(\ 6; C 6 months); age (\ 70; C 70) years; level of edu-
cation (no qualification; some qualification but no degree;
degree holder); work status at recruitment (actively work-
ing; not actively working); and occupational group (man-
agerial/professional; administration/skilled/trades/caring/
sales; operatives/elementary occupations).
2.8 Inference
Boot-strapped bias-corrected and accelerated (BCA) per-
centile 95% confidence intervals (CI) using 10,000 repli-
cations were calculated in Stata version 15 (Stata Corp:
College Station, TX, USA). Follow-up costs were assessed
in two ways. The first examined whether there was a dif-
ference in mean costs associated with consultations, tests
and referrals made during routine follow-up (‘follow-up’
costs). The second approach examined whether there were
differences in mean costs associated with all other resource
use (e.g. GP visits) recorded in the trial (‘total costs’). For
each approach, percentile 95% CI around mean differences
in cost between arms were constructed. All inferential
analysis was conducted using Stata version 15.
2.9 Univariate Sensitivity Analysis
We examined the effect of increasing the salaries for
doctors and nurses to include remuneration for shift work
and overtime [19]. We also examined the effects of
excluding the costs of nurse training from the telephone
arm, which could be considered a routine part of continu-
ing nursing education, and which will likely be lower (per-
patient) outside of the trial setting.
3 Results
3.1 RCT Results
Participant characteristics were similar between arms. The
mean age of participants at randomisation was 65 years.
The median time from diagnosis for participants at ran-
domisation was 12 months. Some 63% of women were
receiving routine follow-up at either 3- or 4-monthly
intervals, 32% at 6-monthly intervals, and 5% at annual
intervals. Other information on participant characteristics is
provided in Beaver et al [14].
Patient-reported anxiety at follow-up was slightly lower
in the telephone arm and within the pre-specified non-in-
feriority limit of - 3.5 (adjusted mean difference 0.7, 95%
CI on an intention-to-treat basis: - 1.9 to 3.3) [14]. There
was no evidence of a difference between groups in satis-
faction with information received (adjusted odds ratio for
lesser satisfaction in hospital group relative to telephone
group: 0.9, 95% CI 0.40 to 2.41). However, more partici-
pants in the hospital group than the telephone group (278
vs. 135%) stated that they did not need any information
(p = 0.003).
There were no differences between arms in quality of
life; this was assessed by a comparison between arms of
each subscale of both EORTC QLQ-C30 instrument (15
subscales/items) and the QLQ-EN24 endometrial cancer
module (13 subscales/items). The only instance of a
between-group difference in either instrument was that
hospital follow-up participants were slightly more likely to
report constipation (p = 0.035) in QLQ-C30. No significant
between-arm differences in physical or psychosocial needs
or time to detection of recurrent disease were reported.
3.2 NHS Costs after 6 and 12 Months
More routine consultations took place in the telephone arm
at six and 12 months. In the hospital arm most of the
consultations at 6 months (Table 2) were with a consultant
(46/121) or registrar (45/121).
Hospital consultations that took place for patients ran-
domised to telephone follow-up were generally not routine
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scheduled follow-up appointments, were conducted only
by senior doctors, and took longer than the consultations
undertaken by equivalent grades of staff in the hospital
arm. Similar patterns were observed at 12 months
(Table 3). Telephone follow-up was not superior in cost
terms at either 6 or 12 months.
Mean consultation duration was longer in the telephone
arm (12.5 min) than in the hospital arm (8.9 min).
Consultants and registrars were responsible for 100%
(6 months) and 88% (12 months) of all hospital-based
consultations in the telephone follow-up arm, compared to
75% (6 months) and 80% (12 months) of consultations in
patients randomised to hospital follow-up. More referrals
were made or ordered in the telephone arm.
At 6 months, mean routine follow-up costs in the tele-
phone arm were higher than in the hospital arm. Nurse
Table 2 Cost of routine follow-up at 6 months post-randomisation
Telephone follow-up
(n = 118 available cases)
Hospital follow-up
(n = 116 available cases)
Mean difference
(95% BCA percentile CI)
N Mean cost per patient (£) N Mean cost per patient (£)
Telephone consultations 123 19.46 0 –
Hospital consultations 14 4.39 121 25.97
Nurse training cost per telephone
consultation
25.56
Testsa 4 10.00 8 3.97
Referralsb 16 9.19 3 4.30
Other healthcare use during period of
follow up
365.40 391.95
Total health system costs 434 426 £8 (- £147 to £141)
Totals health system costs are reported to nearest £1, and may not sum due to rounding
BCA bias-corrected and accelerated, CI confidence interval, CT computed tomography, GP general practitioner
aThe four tests in the telephone arm, and their associated frequencies, were as follows: CT (2), ultrasonography (1), biopsy (1). The eight tests in
the hospital arm, and associated frequencies, were as follows: CT (2), ultrasonography (2), biopsy (1), histology (1), blood sample (1), abdominal
wound swab (1), bile swab (1)
bThe 16 referrals in the telephone arm, and their associated frequencies, were as follows: GP (6), hospital doctor (2), consultant (2), psychologist
(3), physiotherapist (1), complementary therapies (2). The 3 referrals in the hospital arm, and their associated frequencies, were as follows:
hospital doctor (1), physiotherapist (1), and urodynamic therapies (1)
Table 3 Cost of routine follow-up at 12 months post-randomisation
Telephone follow-up (n = 96
available cases)
Hospital follow-up (n = 98
available cases)
Mean difference
(95% BCA percentile CI)
N Mean cost per patient (£) N Mean cost per patient (£)
Telephone consultations 214 37.27 2 0.32
Hospital consultations 17 6.25 200 47.45
Nurse training cost per telephone
consultation
14.41 0.14
Testsa 6 11.88 13 24.64
Referralsb 15 9.83 4 5.47
Other healthcare use during period of
follow up
666.00 744.60
Total health system costs 746 823 – £77 (– £334 to £154)
Totals and subtotals are reported to nearest £1, and may not sum due to rounding
BCA bias-corrected and accelerated, CI confidence interval, CT computed tomography, GP general practitioner
aThe six tests in the telephone arm were one each of CT, ultrasonography, biopsy, histology, high vaginal swab, and mid-stream urine sample.
The 13 tests in the hospital arm, and associated frequencies, were as follows: CT (3), ultrasonography (2), biopsy (2), histology (1), high vaginal
swab (3), mid-stream urine sample (1), blood sample (1)
bThe 15 referrals in the telephone arm, and their associated frequencies, were as follows: GP (6), hospital doctor (2), consultant (3), psychologist
(2), physiotherapist (1), complementary therapies (1). The 4 referrals in the hospital arm, and their associated frequencies, were as follows: GP
(1), physiotherapist (1), radiology (1), and urodynamic therapies (1)
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training costs accounted for approximately 75% of the
difference in follow-up costs at 6 months. This is a con-
sequence of the fixed cost of nurse training being spread
over a modest number of calls. The lower unit cost of
nurse-led telephone consultations is counterbalanced by
the greater number and longer duration of routine consul-
tations. Mean per patient routine follow-up costs at
12 months in the telephone arm were slightly higher than
in the hospital arm.
These cost differences are summarised against the co-
primary outcomes of the ENDCAT trial in the cost-con-
sequences table (Table 4).
3.3 Univariate Sensitivity Analysis of Costs at 6
and 12 Months
The cost comparison at 6 months is affected by the high
fixed cost of nurse training. Excluding the costs of nurse
training from the telephone arm lowers the estimated mean
difference per patient in total costs to - £18 (95% BCA
CI: - £170 to £118) at 6 months, and at 12 months to -
£91 (95% CI: - £347 to £146).
There was little impact on the results of including the
costs of payments for overtime and shift work for doctors
and nurses. The difference in mean total costs was similar
to the base case at both 6 months (mean difference £10:
95% BCA CI - £146 to £146), and 12 months (mean
difference - £72: 95% BCA CI: - £346 to £167).
3.4 Patient Productivity and Transport Costs
A higher proportion of patients in the hospital arm (21/110;
19.1%, Table 5) reported taking time-off work for the
appointment than in the telephone arm (3/111; 2.7%;
Fisher’s exact test p\ 0.001). More than half of those
randomised to the hospital follow-up arm indicated that
they were accompanied by a companion, 12.7% of whom
took time off work. Information on whether patients par-
ticipating in telephone consultations were accompanied
was not recorded.
Average return journey travel costs for attendance at
hospital clinics were estimated to be £11.47 per appoint-
ment, excluding the costs of hospital transport which we
assume is a cost to the NHS rather than a direct patient
cost. More details are provided in Supplementary Table A1
in the supplementary material.
The numbers of patients reporting information relating
to productivity costs was very small: n = 3 patients in the
telephone arm, and n = 19 patients in the hospital arm.
More detail is provided in Supplementary Table A2 in
supplementary material. Mean costs were lower per patient
in the telephone consultation arm (£29) than in the hospital
consultation arm (£57) but inference cannot be reliably T
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conducted given the small number of individuals reporting
data.
3.5 Subgroup Analysis
The results of the subgroup analysis are reported in Sup-
plementary Table A3 in the supplementary material. Sta-
tistical power to detect between-arm differences is very
low, and the evidence available from this analysis does not
offer strong evidence of cost differences amongst the pre-
specified subgroups.
3.6 National Health Service Costs of Recurrent
and Metastatic Cases
Two women (in the hospital arm) with resource use data at
6 months had recurrence/metastases during this period, and
one (in the telephone arm)with resource use data at 12 months
had recurrence/metastases between 6 and 12 months. All
three women underwent some routine follow-up.
In the six-month sample, recurrence was diagnosed 100
and 173 days from randomisation. Mean cost for health-
care deemed to relate only to recurrence was £5597. In the
12-month sample, recurrence was diagnosed at 308 days
after randomisation. This patient is estimated to have
incurred costs of £18,290 associated with relatively heavy
use of a wide variety of different resources.
4 Discussion
4.1 Main Findings
Telephone follow-up was estimated to be cost-neutral, but
not cost saving, for the NHS. Superiority of telephone
follow-up with respect to health system costs was not
demonstrated. There was some evidence that it may be
more efficient for patients and wider society.
4.2 Reasons for Similarity of NHS Costs
Why were NHS costs not lower in the telephone arm? One
reason is that the mean durations of consultation were
longer in the telephone arm, possibly because of the use of
a script for these consultations, and the effects of allocating
20 min for telephone follow-up calls compared to the
10 min scheduled for routine hospital clinic visits. The
telephone intervention was delivered by clinical nurse
specialists within the confines of current staffing levels and
did not take staff away from their usual duties or introduce
new staff to deliver the intervention. Although a period of
training was required, and this was included as a cost in the
base-case analysis, in clinical practice this training could
be incorporated as part of continuing professional
development.
Mean differences in cost are sensitive to training cost,
and to remuneration of doctors and nurses involved in
hospital follow-up, which in practice will be somewhere
between basic salary (included in the main results) and
supplemented income (included in sensitivity analysis). We
reflected the lower capital and overhead costs involved in
providing telephone follow-up, although this might
understate the costs savings if lower numbers of hospital
visits lead to more efficient long-term hospital capital
planning.
More referrals were made or ordered in the telephone
arm. This finding was also observed in a similar economic
evaluation for breast cancer patients [22]. A study on
nurse-led follow-up for prostate cancer patients also indi-
cated that nurses made more referrals than their medical
colleagues [24]. The possibility of a greater number of
referrals when nurses substitute for doctors was noted in a
Table 5 Patient and companion
time for hospital consultations
Telephone consultation Hospital consultation
N Response N Response
Presence of companion? N/Aa N/Aa 111 responses Yes—61 (55.0%)
No—50 (44.0%)
Time off work for the appointmentb
Patient 111 responses Yes—3 (2.7%)
No—108 (97.3%)
110 responses Yes—21 (19.1%)
No—89 (80.9%)
Companion N/Aa N/Aa 63 responses Yes—8 (12.7%)
No—55 (87.3%)
aPatients were asked whether they had been accompanied to a hospital consultation only. Any accompa-
niment for telephone consultations that may have taken place was not recorded during the trial
bTwo responses to this question indicated that no time off work had actually been taken because of
compensating shift changes or the time being made up in other ways. These two patients were assumed to
have incurred no productivity cost, which is a conservative assumption
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more general evaluation of advanced nursing roles in 12
developed countries [25].
The structured nature of the intervention in the END-
CAT trial encouraged patients to voice their information
needs and concerns. Hospital doctors in busy hospital
clinics do not tend to follow a structured protocol for the
consultation and appointments are brief [4]. It could be
argued that the nurses in the telephone arm were
responsive to patients’ needs and concerns and made
appropriate referrals. Alternatively, the nurses were
inexperienced at delivering the telephone intervention at
the outset and may have made additional referrals in order
to ensure they did not miss anything. As most referrals in
the telephone arm were made to a GP, issues may have
arisen that were unrelated to the cancer diagnosis and
were in response to more general questions about changes
in condition.
Fewer patients reported taking time off work for the
telephone consultation, while more than half of patients
had a companion present at hospital consultations. The
average return journey hospital travel cost of approxi-
mately £11 will be incurred for every hospital consulta-
tion. Travel and productivity costs were not collected for
each consultation, which means that changes in patient
circumstances were not captured. Telephone follow-up
was associated with less likelihood of delay in undergoing
the consultation; intervention patients reported high levels
of satisfaction with the timeliness of their consultations
[14].
4.3 Strengths
The ENDCAT trial provides the only findings published
[14] to date of an evaluation of hospital versus tele-
phone follow-up for patients with endometrial cancer. The
design of the intervention evaluated in the trial, and the
subject of the economic analysis described in this study,
built on evidence generated by previous examinations of
nurse-led telephone follow-up [26, 27].
The economic analysis adds to the limited evidence base
(discussed below) on the cost implications of telephone
follow-up after treatment for cancer. The economic anal-
ysis was based on a prospective analysis of detailed
patient-level data, and encompassed elements of health
system, personal and societal perspectives. The trial was
conducted in five centres in the north-west of England, and
there is no obvious reason why the findings could not be
generalizable to other NHS contexts. The implications for
other countries are less clear, and will depend on the fre-
quency of routine follow-up, the pressure on hospital clinic
space, and the seniority of staff involved in hospital-based
follow-up.
4.4 Limitations
The study was not powered to detect differences in cost,
and the failure to reject the null hypothesis of no difference
in healthcare cost may reflect a Type II error. However, the
relatively narrow confidence interval around the point
estimate for differences in routine NHS costs at 12 months
suggests that nurse-led telephone follow-up was approxi-
mately cost-neutral.
The economic analysis was limited to one year from
randomisation, which does not reflect the full duration of
follow-up that women will undergo in recovering from
endometrial cancer. However, trial participants were at
various stages post-diagnosis, with a median of 12 months
(Interquartile range: 4 to 24 months). Some 63% of women
were receiving routine follow-up at either 3- or 4-monthly
intervals, 32% at 6-monthly intervals, and 5% at annual
intervals. The 12-month period of trial follow-up may
therefore reflect the experiences of women at different
stages of clinical follow-up, but the evidence presented
here is necessarily an approximation to—rather than a
direct quantitative characterisation of—longer-term
outcomes.
The design of the trial meant that disease-specific
quality-of-life data were collected post-randomisation only
at the first post-baseline appointment, the timing of which
depended on whether participants were on a 3-monthly,
6-monthly or annual follow-up schedule. The economic
analysis was therefore restricted to a cost-consequence
analysis, which is necessarily narrower in scope than
alternative study designs that—for example—measure
disease-specific or generic measures of quality of life at
baseline and all subsequent follow-up time points. Recall
bias may have affected self-report of resource use not
collected from medical records, although this bias may
have affected each arm in a similar fashion.
We do not have information on whether companions
took time off work or incurred other costs to be present
during telephone consultations. However, we consider that
any effect on costs is likely to be modest.
4.5 Other Evidence
The amount of evidence available for cost analysis of
similar interventions in endometrial and other cancers is
limited [28], although there is a growing literature in nurse
follow-up after treatment for breast cancer [29]. A UK trial
[26] comparing nurse-led telephone follow-up for patients
recovering from breast cancer to routine hospital follow-up
also observed longer and more frequent consultations in the
telephone arm. Expensive telephone consultation costs, and
the use of junior doctors in the hospital arm, meant that
NHS costs were significantly higher in the telephone arm,
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although patients randomised to telephone follow-up also
reported lower travel and productivity costs.
A trial in Sweden [30] found the costs of on-demand and
scheduled nurse follow-up to be 20% lower, and signifi-
cantly so, than routine follow-up after treatment for breast
cancer. The results were also sensitive to the costs of
telephone consultations. A Dutch economic evaluation [31]
of four follow-up strategies after treatment for breast can-
cer, involving combinations of educational programmes in
conjunction with nurse-led and telephone follow-up,
observed modest cost-differences but found that nurse-led
follow-up combined with an educational programme was
cost-effective. A systematic review of breast cancer follow-
up [29] found that considerations pertaining to the design
of follow-up, such as frequency, can influence cost
differences.
4.6 Summary Implications for Policy Makers
Nurse-led telephone follow-up is an effective alternative
for patients at low risk of recurrence. Nurse specialists are
limited in number and are unlikely to have the resources to
provide follow-up care to all patients diagnosed with low-
risk cancers. However, a survey of the adult cancer
workforce reported that oncology nurses perceived that
they had the skills to manage long-term follow-up [32].
Nurse-led telephone follow-up is therefore supported by
clinical evidence of effectiveness, has a workforce capable
of delivering the intervention, and is cost-neutral for the
NHS. A reduction in the number of outpatient appoint-
ments with more self-management approaches and patient
initiated follow-up services is currently being advocated
[33]. However, until these initiatives are fully imple-
mented, telephone follow-up presents providers and com-
missioners of services with a viable alternative, freeing up
doctor time and clinic space.
5 Conclusion
Overall, the evidence from the ENDCAT trial suggests that
there may be an economic case for considering the use of
telephone follow-up for this patient group. The intervention
is not more expensive than hospital follow-up at
12 months, is associated with lower personal and produc-
tivity costs, and is not associated with psychological
detriment.
Acknowledgements We thank all the patients who took part in the
study. Administrative support was provided by Simone Finley. We
are grateful to Jane Burnell for statistical support and for advice
concerning the collection and interpretation of data. An early version
of this work was presented at the Cancer Outcomes Conference 2015
in Belfast.
Author Contributions PMH and KB conceived the ENDCAT study.
PMH, KB, SW, CS, and WH contributed to the overall design of the
ENDCAT trial. WH designed the economic analysis of the ENDCAT
RCT. PD and WH were responsible for conducting the economic
analysis. All authors had a role in interpreting the data. PD wrote the
first draft of this article, and all authors contributed to subsequent
revisions. All authors approved the final draft for submission.
Compliance with Ethical Standards
All patients provided written consent before registration in the trial.
Ethical approval was granted by the National Research Ethics Service
(11/NW/0648) and approval from the Research & Development
departments of all participating centres was obtained prior to
recruitment.
The study was funded by the National Institute of Health Research
(NIHR) under the Research for Patient Benefit programme (Grant
Reference: PB-PG-0610-22123) (UKCRN ID: 11016; ISRCTN:
75220876). The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
The funder had no role in study design, data collection, data analysis,
data interpretation, or writing the report.
PD is a member of the MRC Integrative Epidemiology Unit at the
University of Bristol which is supported by the Medical Research
Council and the University of Bristol (MC_UU_12013/1,
MC_UU_12013/9). PD acknowledges support from a Medical
Research Council Skills Development Fellowship (MR/P014259/1).
PD, KB, SW, CS, PMH, and WH declare no competing interests.
Availability of Data and Materials The research team will consider
requests for sharing of patient level data. Consent for data sharing was
not obtained but the presented data are anonymised and risk of
identification is low. Requests should be made to Professor Kinta
Beaver.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Maddams J, Utley M, Moller H. Projections of cancer prevalence
in the United Kingdom, 2010–2040. Br J Cancer.
2012;107(7):1195–202.
2. Maher J, McConnell H. New pathways of care for cancer sur-
vivors: adding the numbers. Br J Cancer. 2011;8(105 Suppl
1):S5–10.
3. Lajer H, Jensen MB, Kilsmark J, Albaek J, Svane D, Mirza MR,
et al. The value of gynecologic cancer follow-up: evidence-based
ignorance? Int J Gynecol Cancer. 2010;20(8):1307–20.
4. Jefford M, Rowland J, Grunfeld E, Richards M, Maher J, Glaser
A. Implementing improved post-treatment care for cancer sur-
vivors in England, with reflections from Australia, Canada and
the USA. Br J Cancer. 2013;108(1):14–20.
5. Pagh A, Vedtofte T, Lynggaard CD, Rubek N, Lonka M,
Johansen J, et al. The value of routine follow-up after treatment
for head and neck cancer. A National Survey from DAHANCA.
Acta Oncol. 2013;52(2):277–84.
P. Dixon et al.
6. NHS England. Achieving world class cancer outcomes: taking
the strategy forward. 2016. https://www.england.nhs.uk/wp-
content/uploads/2016/05/cancer-strategy.pdf. Accessed 4 Apr
2018.
7. Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The
clinical value and the cost-effectiveness of follow-up in
endometrial cancer patients. Int J Gynecol Cancer.
2004;14(5):931–7.
8. Stewart B, Wild C, editors. World Cancer Report 2014: Inter-
national Agency for Research on Cancer. Lyon: World Health
Organization; 2014.
9. Plataniotis G, Castiglione M, On behalf of the EGWG.
Endometrial cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl
5):v41–5.
10. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U,
Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th
Annual Report on the Results of Treatment in Gynecological
Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–43.
11. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen
E, Vergote I. Endometrial cancer. Lancet.
2005;366(9484):491–505.
12. Jeppesen MM, Mogensen O, Hansen DG, Iachina M, Korsholm
M, Jensen PT. Detection of recurrence in early stage endometrial
cancer—the role of symptoms and routine follow-up. Acta Oncol.
2017;56(2):262–9.
13. Beaver K. Comparing hospital and telephone follow up for
women treated for endometrial cancer (ENDCAT): ENDometrial
CAncer Telephone follow up trial). ISRCTN Trial Registry 2011.
https://doi.org/10.1186/ISRCTN75220876.
14. Beaver K, Williamson S, Sutton C, Hollingworth W, Gardner A,
Allton B, et al. Comparing hospital and telephone follow-up for
patients treated for stage–I endometrial cancer (ENDCAT trial): a
randomised, multicentre, non-inferiority trial. BJOG Int J Obstet
Gynaecol. 2017;124(1):150–60.
15. Spielberger C. State-trait anxiety inventory. Mountain View:
Consulting Psychologists Press; 1983.
16. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez NJ, et al. The European organization for research and
treatment of cancer QLQ-C30: a quality-of-life instrument for use
in international clinical trials in oncology. J Natl Cancer Inst.
1993;85(5):365–76.
17. Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-
Franse LV, Radisic VB, et al. Psychometric validation of the
European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire-Endometrial Cancer Module
(EORTC QLQ-EN24). Eur J Cancer. 2011;47(2):183–90.
18. Coast J. Is economic evaluation in touch with society’s health
values? BMJ. 2004;329:1233–6.
19. Curtis L. Unit costs of health and social care 2013. Canterbury:
Personal Social Services Research Unit; 2013.
20. Department of Health. NHS Reference Costs 2012/13. London;
2013. https://www.gov.uk/government/publications/nhs-
reference-costs-2012-to-2013. Accessed 5 Apr 2018.
21. HM Treasury. GDP deflators at market prices, and money GDP
November 2017 (Autumn Budget 2017). 2017 03/01/2018];
Available from: https://www.gov.uk/government/statistics/gdp-
deflators-at-market-prices-and-money-gdp-november-2017-autumn-
budget-2017.
22. Nicolaije KAH, Ezendam NPM, Vos MC, Boll D, Pijnenborg
JMA, Kruitwagen RFPM, et al. Follow-up practice in endometrial
cancer and the association with patient and hospital characteris-
tics: a study from the population-based PROFILES registry.
Gynecol Oncol. 2013;129(2):324–31.
23. Vistad I, Moy BW, Salvesen HB, Liavaag AH. Follow-up rou-
tines in gynecological cancer—time for a change? Acta Obstet
Gynecol Scand. 2011;90(7):707–18.
24. Helgesen F, Andersson SO, Gustafsson O, Varenhorst E, Goben
B, Carnock S, et al. Follow-up of prostate cancer patients by on-
demand contacts with a specialist nurse: a randomized study.
Scand J Urol Nephrol. 2000;34(1):55–61.
25. Delamaire M, Lafortune G. Nurses in Advanced Roles. OECD
Health Working Papers. 2010; No 54.
26. Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Wil-
liamson S, Hindley A, et al. Comparing hospital and telephone
follow-up after treatment for breast cancer: randomised equiva-
lence trial. BMJ. 2009;338:a3147.
27. Beaver K, Campbell M, Williamson S, Procter D, Sheridan J,
Heath J, et al. An exploratory randomized controlled trial com-
paring telephone and hospital follow-up after treatment for col-
orectal cancer. Colorectal Dis. 2012;14(10):1201–9.
28. Dickinson R, Hall S, Sinclair JE, Bond C, Murchie P. Using
technology to deliver cancer follow-up: a systematic review.
BMC Cancer. 2014;14:311.
29. van Hezewijk M, Elske van den Akker M, van de Velde Velde
CJH, Scholten AN, Hille ETM. Costs of different follow-up
strategies in early breast cancer: a review of the literature. Breast.
2012;21(6):693–700.
30. Koinberg I, Engholm GB, Genell A, Holmberg L. A health
economic evaluation of follow-up after breast cancer surgery:
Results of an rct study. Acta Oncol. 2009;48(1):99–104.
31. Kimman ML, Dirksen CD, Voogd AC, Falger P, Gijsen BCM,
Thuring M, et al. Economic evaluation of four follow-up strate-
gies after curative treatment for breast cancer: results of an RCT.
Eur J Cancer. 2011;47(8):1175–85.
32. Faithfull S, Samuel C, Lemanska A, Warnock C, Greenfield D.
Self-reported competence in long term care provision for adult
cancer survivors: a cross sectional survey of nursing and allied
health care professionals. Int J Nurs Stud. 2016;53:85–94.
33. Department of Health, Macmillan Cancer Support & NHS
Improvement. Living with and beyond cancer: taking action to
improve outcomes (an update to the 2010 The National Cancer
Survivorship Initiative Vision). London; 2013.
34. Office of National Statistics. Annual Survey of Hours and
Earnings, 2013 Provisional Results. Available from: http://
webarchive.nationalarchives.gov.uk/20160107081242/, http://www.
ons.gov.uk/ons/rel/ashe/annualsurvey-of-hours-and-earnings/2013-
provisional-results/index.html. Accessed 5 Apr 2018.
35. Liu F, Treharne C, Culleton B, Crowe L, Arici M. The financial
impact of increasing home-based high dose haemodialysis and
peritoneal dialysis. BMC Nephrol. 2014;15(1):1–12.
36. Curtis L. Unit costs of health and social care 2011. Canterbury:
Personal Social Services Research Unit; 2011.
37. Curtis L. Unit costs of health and social care 2010. Canterbury:
Personal Social Services Research Unit; 2010.
Costs of Hospital Versus Telephone Follow-Up after Endometrial Cancer
